Francesco Patalano

TL;DR: Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year and showed not only noninferiority but also superiority in reducing the annual rate of all COPd exacerbations.

TL;DR: In patients with COPD without frequent exacerbations on long‐term triple therapy, the direct de‐escalation to indacaterol/glycopyrronium led to a small decrease in lung function, with no difference in exacerbations.

TL;DR: Findings support the use of theLABA/LAMA, QVA149 as an alternative treatment, over LABA/inhaled corticosteroid, in the management of moderate-to-severe COPD patients (GOLD B and GOLD D) with a history of ≤1 exacerbation in the previous year.

TL;DR: Prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD.

TL;DR: Indacaterol/glycopyrrolate twice daily can be an alternative treatment option for the management of symptomatic patients with moderate-to-severe COPD and was statistically superior in terms of FEV1 area under the curve from 0-12 hours compared with its monocomponents.